Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cyclerion Therapeutics (CYCN) Net Income (2019 - 2025)

Cyclerion Therapeutics (CYCN) has 7 years of Net Income data on record, last reported at -$1.0 million in Q3 2025.

  • For Q3 2025, Net Income rose 10.82% year-over-year to -$1.0 million; the TTM value through Sep 2025 reached -$3.6 million, down 222.07%, while the annual FY2023 figure was $7.3 million, 128.38% up from the prior year.
  • Net Income reached -$1.0 million in Q3 2025 per CYCN's latest filing, up from -$1.7 million in the prior quarter.
  • Across five years, Net Income topped out at $13.5 million in Q3 2023 and bottomed at -$16.2 million in Q2 2021.
  • Average Net Income over 5 years is -$4.4 million, with a median of -$3.1 million recorded in 2023.
  • Peak YoY movement for Net Income: surged 398.25% in 2023, then plummeted 108.37% in 2024.
  • A 5-year view of Net Income shows it stood at -$14.3 million in 2021, then surged by 186.44% to $12.4 million in 2022, then rose by 8.71% to $13.5 million in 2023, then crashed by 96.27% to $502000.0 in 2024, then plummeted by 300.4% to -$1.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Income were -$1.0 million in Q3 2025, -$1.7 million in Q2 2025, and -$1.5 million in Q1 2025.